Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
HERON THERAPEUTICS, INC. (HRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates • Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise • Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigation • New management team in place • Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million SAN DIEGO, August 14, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and six months ended June 30, 2023 and highlig..."
05/11/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates • Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022 • Appointment of Craig Collard as Chief Executive Officer and Jason Grillot as Vice President , Sales and Marketing, of the Acute Care Franchise. SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates. First quarter 2023 net product s..."
03/23/2023 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates - Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE™Commercially Launched on March 6, 2023 - - ZYNRELEF® Net Product Sales for Fourth Quarter of 2022 Increased 44% Over Prior Quarter to $3.9 Million - - Oncology Care Franchise Net Product Sales for 2022 Grew 17% Over Prior Year to $97.5 Million – SAN DIEGO, March 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results ..."
11/08/2022 8-K Quarterly results
Docs: "®"
05/09/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates - ZYNRELEF ® has received 260 formulary approvals since initial launch in July 2021, with over a 90% hospital approval rate and over 60% of approvals have been for unrestricted usage -"
11/03/2021 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF ® net product sales of $2.1 million in its first quarter of launch with 160 unique accounts already purchasing ZYNRELEF and 50% of those accounts reordering -"
05/10/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "European Commission Authorization for ZYNRELEF™ for the Treatment of Postoperative Pain: In September 2020, the European Commission granted a marketing authorization for ZYNRELEF for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. The marketing authorization follows the European Medicines Agency’s positive opinion from the Committee for Medicinal Products for Human Use in July 2020. The EC’s centralized marketing authorization is valid for the 27 countries that are members of the European Union , and the other countries in the European Economic Area . We are currently assessing the evolving global environment for pharmaceuticals and developing a coordinated global marketing strategy, and at this time we anticipate making ZYNRELEF ava..."
05/06/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress SAN DIEGO, Calif.——May 9, 2019— Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress. Recent Corporate Progress"
02/22/2019 8-K Quarterly results
11/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress"
05/10/2018 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress SAN DIEGO, Calif.——May 10, 2018— Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three months ended March 31, 2018 and highlighted recent corporate progress. Recent Corporate Progress"
02/27/2018 8-K Quarterly results
Docs: "Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress SAN DIEGO, Calif.——February 27, 2018— Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress. Recent Corporate Progress"
11/06/2017 8-K Quarterly results
Docs: "Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress SAN DIEGO, Calif. - - November 6, 2017 - Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three and nine months ended September 30, 2017 and highlighted recent corporate progress. Recent Corporate Progress"
05/10/2017 8-K Form 8-K - Current report
02/23/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress"
08/08/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
02/19/2016 8-K Quarterly results
Docs: "Heron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress"
11/06/2015 8-K Quarterly results
Docs: "Heron Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Progress"
08/07/2015 8-K Quarterly results
Docs: "Heron Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Progress"
05/08/2015 8-K Quarterly results
Docs: "Heron Therapeutics Announces First Quarter 2015 Financial Results and Corporate Progress"
03/13/2015 8-K Quarterly results
Docs: "Heron Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Progress"
11/06/2014 8-K Quarterly results
Docs: "Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights",
"Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK 1 Receptor Antagonist for Prevention of CINV"
05/08/2014 8-K Quarterly results
Docs: "Heron Therapeutics Announces First Quarter 2014 Financial Results"
03/05/2014 8-K Quarterly results
Docs: "Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress"
11/12/2013 8-K Form 8-K - Current report
08/12/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy